FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
Today, the U.S. Food and Drug Administration approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human cells) adenoviral vector based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Pharmaceuticals